学会発表（国際）
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.